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PH patients than in the controls. The mean transpulmonary 
gradient (arterial-mixed venous) was negative in the PH 
group and positive in the controls. An inverse correlation 
was found between the arterial blood platelet serotonin 
content and pulmonary hemodynamics. Plasmatic sero-
tonin levels did not differ between the PH and control 
groups.  Conclusion: The lower platelet serotonin concentra-
tion in PH patients compared with unaffected controls is an 
unprecedented finding. The negative transpulmonary plate-
let serotonin gradient and the strong negative correlation of 
arterial blood platelet serotonin with pulmonary hemody-
namics might indicate increased serotonin uptake in the 
lungs of PH patients. 
 
Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Pulmonary hypertension (PH) comprises a group of 
relatively rare disorders with a consistently progressive 
course and a dismal prognosis  [1] . In the last decade, ma-
jor advances in the pathogenetic understanding of pul-
monary vascular diseases have led to better treatment op-
tions and prognosis  [2] . These progresses are also reflect-
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 Abstract 
 Background: The serotonin system has repeatedly been as-
sociated with the pathogenesis of pulmonary hypertension 
(PH).  Objective: To comparatively analyze plasmatic and in-
trathrombocytic serotonin levels in arterial and mixed ve-
nous blood of patients with PH and unaffected controls to 
elucidate pulmonary serotonin metabolisms.  Patients and 
Methods: Catheters were placed in the radial and pulmo-
nary artery in patients with PH (n = 13) for diagnosis and in 
age-matched controls (n = 6) undergoing percutaneous clo-
sure of the patent foramen ovale. Arterial and mixed venous 
blood samples were immediately centrifuged to obtain plas-
ma and platelets and thereafter frozen at –20  °  C. After careful 
thawing, plasmatic and platelet serotonin levels were deter-
mined by ELISA.  Results: PH was classified as arterial in 4 and 
chronic thromboembolic in 9 patients with a mean pulmo-
nary artery pressure of 37 (interquartile range: 32–43) mm 
Hg. Platelet serotonin content was significantly lower in the 
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ed in newer PH classifications and evolving therapies  [2, 
3] . Nevertheless, the major part of the etiopathogenesis of 
PH is still incompletely understood.
 The serotonin system seems to be involved in the 
pathogenesis of PH. In the 1960s, an association between 
PH and the anorexigen aminorex was identified, leading 
to the withdrawal of aminorex from the market in 1972 
 [4] . In the 1980s, fenfluramine was the second anorexigen 
linked to PH  [5] . These anorexigens (fenfluramine,  D -
fenfluramine and aminorex) have been shown to increase 
the levels of circulating serotonin (5-hydroxytryptamine, 
5-HTT) by inhibiting its reuptake in neurons and plate-
lets, inducing platelet release of serotonin, and by block-
ing its degradation through interaction with the mono-
amine oxidase enzymes  [6–8] . Serotonin is a potent pul-
monary vasoconstrictor but causes profound vasodilation 
in the systemic vasculature  [7–9] . The different effects of 
serotonin on the two circulatory systems are similar to 
those observed under hypoxemia. Moreover, the effects 
of serotonin are intensified under hypoxemic conditions 
and the administration of catecholamines  [8, 10] . Sero-
tonin also plays an important role in pulmonary vascular 
remodeling and proliferation  [11–14] . An increase in plas-
ma serotonin associated with PH was first described in a 
patient with a rare hereditary thrombocytopathy, a defect 
in the serotonin-storing   -granules  [15] . Shortly thereaf-
ter, serotonin was found to be increased in the plasma of 
PH patients  [16] . In in vivo studies, intravenous serotonin 
treatment of chronically hypoxic rats for 2 weeks in-
creased pulmonary artery pressure, right-ventricular hy-
pertrophy and pulmonary vascular remodeling  [17] . The 
increased plasma serotonin was ascribed to platelet acti-
vation, which induces the release of the serotonin stored 
in granules into the extracellular space  [18] . A pathoge-
netic role of platelet activation in PH patients was sup-
ported by the clinical efficacy of prostacyclins  [19] , which 
are potent inhibitors of platelet activation. However, ele-
vated plasma serotonin levels did not correlate with plate-
let activation, and treatment with epoprostenol did not 
affect plasma serotonin levels in a later study  [20] .
 Serotonin is an endogenous vasoactive indolamine 
found mainly in enterochromaffin tissue, brain and 
blood platelets. Approximately 90% of serotonin is locat-
ed in the intestines, where it plays a key role in mechano- 
and chemotransduction. Most of the serotonin released 
from enterochromaffin cells reaches the portal circula-
tion, where it is avidly taken up and stored in small elec-
tron-dense granules within platelets  [21] . Platelet half-life 
of serotonin is in the range of 33–48 h; plasma serotonin 
is either catabolized by monoamine oxidase A in the liv-
er, or taken up and actively transported via an integral 
membrane protein, the serotonin transporter (5-HTT), 
to the lung to be degraded inside endothelial and smooth 
muscle cells by monoamine oxidase B. These processes 
result in very low levels of free serotonin in plasma under 
normal physiological conditions  [22] .
 As serotonin seems to play a crucial role in pulmonary 
vasoconstriction and proliferation and the lung is the ma-
jor organ to metabolize serotonin produced in entero-
chromaffin cells of the gastrointestinal tract, we hypoth-
esized that possible differences in the serotonin content 
in platelets and platelet-free plasma (PPF) in mixed ve-
nous and arterial blood between PH patients and healthy 
controls may add interesting information concerning the 
serotonin metabolism and its role in PH.
 Patients and Methods 
 Consecutive patients scheduled for a diagnostic right-heart 
catheterization at the PH clinic of the University Hospital of Zu-
rich, Switzerland, were prospectively included upon written in-
formed consent. PH was defined as mean pulmonary artery pres-
sure (mPAP)  6 25 mm Hg with a pulmonary capillary occlusion 
pressure  ^  15 mm Hg. Patients were grouped according to the 
WHO classification into pulmonary arterial hypertension (PAH) 
and chronic thromboembolic pulmonary hypertension (CTEPH). 
Diagnostic right-heart catheters (Swan Ganz; Edwards, Switzer-
land) were placed via a jugular vein and a radial arterial catheter. 
Cardiac output was assessed by thermodilution (Baxter/Edwards, 
USA). Hemodynamic data were assessed according to standard 
procedures and noted (mPAP, pulmonary capillary occlusion 
pressure, cardiac index, pulmonary vascular resistance, PVR, and 
arterial and mixed venous oxygen pressures and tensions). After 
a 10-min rest, radial arterial and mixed venous blood samples
(5 ml of each) were atraumatically collected into citrate tubes. 
Similarly collected arterial and mixed venous blood samples from 
age-matched control patients with normal mPAP and PVR re-
ferred for heart catheterization due to other diseases (mainly pat-
ent foramen ovale closure due to the occurrence of transient isch-
emic attacks) served as controls. The blood was immediately 
transferred to the laboratory and centrifuged at 200  g at room 
temperature for 10 min to obtain platelet-rich plasma (PRP), and 
in 0.5 ml thereof platelets were counted and thereafter adjusted to 
  350,000/  l; 300   l PRP was added to 2.7 ml of 0.9 NaCl and 
centrifuged at 4,500  g at 4  °  C for 10 min. The supernatant was dis-
carded and 600   l sterile bidistilled water was added to the pellet. 
This amount was aliquoted in two tubes (150 ml each) and frozen 
at –20  °  C. The remainder of the plasma from the first centrifuga-
tion was again centrifuged at 4,500  g at 4  °  C for 10 min to obtain 
platelet-poor plasma (PPP) and frozen at –20  °  C.
 The frozen aliquots of PRP and PPP simultaneously obtained 
from arterial and mixed venous blood were defrosted on ice and 
serotonin was determined by competitive ELISA after derivatiza-
tion of serotonin to N-acetylserotonin (IBL; Germany). The 
transpulmonary serotonin contents in plasma and platelets were 
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calculated as follows: arterial minus respective mixed venous se-
rotonin content.
 Results are expressed as medians and interquartile ranges. 
The Mann-Whitney U test was used to compare means between 
groups. Pearson’s correlation and scatter plots were used to show 
relationships between parameters. Differences in p  ! 0.05 were 
considered statistically significant. Statistical analysis was per-
formed using SPSS (version 17.0).
 The study was approved by the local ethical review board 
(University of Zurich, Switzerland).
 Results 
 Thirteen patients with PH and 6 controls were includ-
ed in the study. Patient characteristics are shown in  ta-
ble  1 . Patients were mostly female, in New York Heart 
Association class III and were severely exercise limited 
(median 6-min walk distance 450 m, range 400–500). 
Four patients suffered from PAH (WHO class I; 2 idio-
pathic and 2 associated with connective tissue disease) 
and 9 patients had thromboembolic disease (WHO class 
IV). The two groups did not differ in clinical, hemody-
namic and measured blood parameters, thus we analyzed 
them together. All 6 controls had normal pulmonary he-
modynamics. Plasma serotonin levels in arterial and 
mixed venous blood were similar in PH patients and con-
trols. Similarly, the transpulmonary plasma serotonin 
gradient (arterial serotonin minus mixed venous sero-
tonin) did not differ between patients and controls ( ta-
ble 2 ). However, the platelet serotonin level was signifi-
cantly lower in PH patients compared with controls, par-
ticularly in arterial blood. The transpulmonary platelet 
serotonin content was negative in PH patients, whereas it 
was positive in controls. We found a strong overall nega-
tive correlation of pulmonary hemodynamics with the 
arterial platelet serotonin content (R = –0.850, p  ! 0.001 
PH Controls 
Patients, n (%) 13 (100) 6 (100)
Females/males, n (%) 10/3 (77/23) 2/4 (33/67)
Age, years 67 (60–73) 61 (53–67)
PH classification, n (%)
PAH 4 (31)
CTEPH 9 (69)
mPAP, mm Hg 37 (32–43) 12 (11–13)
PVR, dynsm–5 640 (500–861) 107 (89–109)
Cardiac index, l/min/m2 2 (1.8–2.4) 2.8 (2.7–2.8)
Mixed venous oxygen saturation 51 (50–56) 75 (75–76)
NYHA class I/II/III/IV, n (%) 0/2/8/3 (0/15/62/23) 1/0/0/0 
6-min walking distance, m 450 (400–500) not performed
D ata are medians (interquartile ranges) and numbers (%).
Table 1.  Patient characteristics
PH (n = 13) Controls (n = 6)
PPF, mixed venous 5.4 (4.0–7.9) 6.3 (5.5–6.9)
PPF, arterial 6.3 (3.1–7.1) 6.6 (5.3–6.6)
Transpulmonary plasma gradient –0.3 (–1.0–0.9) –0.1 (–0.7–0.2)
Platelets, mixed venous 41 (36–74)* 99 (80–152)
Platelets, arterial 39 (27–52)** 160 (117–178)
Transpulmonary platelet gradient –9.5 (–20–6.5) 30 (7–41)
M edians (quartile ranges). * p = 0.013, ** p < 0.001, vs. controls. There was no sig-
nificant difference in the transpulmonary platelet gradient between the PH and control 
groups (p = 0.32).
Table 2.  Serotonin (ng/ml) in plasma and 
platelets
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for mPAP and R = –0.807, p  ! 0.001 for PVR,  fig. 1 ) and 
the mixed venous platelet serotonin content (R = –0.566, 
p = 0.18 for mPAP and R = –0.636, p = 0.006 for PVR). 
For the arterial blood, this correlation persisted even after 
looking only at PH patients (R = –0.567, p = 0.054 for 
mPAP and R = –0.700, p = 0.011 for PVR,  fig. 1 ).
 Discussion 
 Our results firstly demonstrate a lower platelet sero-
tonin content in PH patients compared with unaffected 
controls, especially in the arterial blood, resulting in a 
negative transpulmonary platelet serotonin content in 
PH patients, whereas it was positive in unaffected con-
trols.
 The serotonin system seems to play a role in PH, but 
the exact mechanisms remain to be elucidated  [23] . Most 
probably, all three components of the serotonin system 
(synthesis, transporter and receptors) seem to be involved 
via a complex interaction and regulation system. Al-
though elevated plasma serotonin levels have been found 
previously in PH patients compared with healthy con-
trols  [16] , a direct link between plasma serotonin and PH 
could not be established  [20] . In our study, plasma sero-
tonin levels did not significantly differ between the PH 
patients and the controls. The major reason for these dif-
ferences may be that the plasma half-life of serotonin is 
very short. Conversely, we found a decreased platelet se-
rotonin content in PH patients compared with controls. 
To our knowledge, platelet serotonin levels have not been 
described in PH patients so far. Since the half-life of plate-
let serotonin is considerably longer than the half-life of 
plasma serotonin, it might represent a more robust mea-
surement parameter. Although reference values of plate-
let serotonin levels in healthy controls have scarcely been 
published, gender differences have not been reported but 
levels seem to decrease with age  [24] . As patients and con-
trols were matched for age, we can exclude this confound-
er in our study. Interestingly, the difference in the platelet 
serotonin content between patients and controls was 
most pronounced in the arterial blood, resulting in a neg-
ative transpulmonary platelet gradient in PH, whereas in 
controls this gradient was positive. It could therefore be 
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hypothesized that in PH patients serotonin is consumed 
or degraded in the lung, either through enhanced mono-
amine oxidase activity or increased uptake by the stressed 
endothelium, e.g. by increased serotonin uptake by 
5-HTT on pulmonary vascular endothelial and smooth 
muscle cells, with increased 5-HTT expression on these 
cells in PAH patients compared with controls  [25–27] . 
However, we do not know why platelet serotonin values 
were considerably higher in arterial compared with 
mixed venous blood in controls. Thus, further studies 
unraveling the mechanisms of serotonin metabolism in 
the healthy and diseased human lung are warranted. Fur-
thermore, a strong negative correlation was found be-
tween the arterial platelet serotonin content and pulmo-
nary hemodynamics. This correlation even persisted, 
when we looked only at PH patients. This inverse correla-
tion between pulmonary hemodynamics and the arterial 
platelet serotonin content might indicate that the strain 
on the pulmonary vessel wall due to PH might lead to an 
increased degradation of platelet serotonin. However, 
further research including in vivo models is needed to 
better elucidate the pathophysiological function of the se-
rotonin system in PH.
 Our study is limited by the small sample size and 
methodological issues. However, PH is a rare disease and 
immediate processing of patient blood obtained during 
right-heart catheterization is a logistical challenge. More-
over, as we processed the blood of patients and controls 
similarly, any methodological flaw should have been 
equally distributed among patients and controls. We in-
cluded patients with PAH and CTEPH in our study, con-
ditions with elevated pulmonary artery pressures due to 
different etiologies. It remains to be determined to date 
whether the involvement of the serotonin system differs 
depending on the etiology of PH and whether the etiol-
ogy of PH might have affected the results. However, in 
our small study we did not find differences in blood se-
rotonin levels between PAH and CTEPH. It is open to 
discussion whether patients with patent foramen ovale 
comprise an optimal control group for PH patients and it 
cannot be excluded that some of the differences found 
might be attributed to a different serotonin metabolism 
in the controls. However, it would have been ethically dif-
ficult to catheterize healthy people since all controls in-
cluded lacked exercise limitation or dyspnea and had nor-
mal pulmonary hemodynamics.
 In summary, our finding of decreased platelet sero-
tonin in PH compared to unaffected controls is novel. 
Together with the clearly negative correlation of arterial 
blood platelet serotonin with pulmonary vascular pres-
sure and resistance, these findings may point towards in-
creased intrapulmonary serotonin uptake in PH.
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